| 产品详情 |
| Edit |   |
|---|
| Product Name | Synuclein, alpha, Wild type, Recombinant, Human, 140aa |
|---|
| Description | Purity ~95% (SDS-PAGE). Parkinson's disease (PD) is a common neurodegenerative disorder with a lifetime incidence of ~2 percent; the clinical manifestations of this neurodegenerative disorder include resting tremor, muscular rigidity, bradykinesia, and postural instability. A relatively specific pathological feature accompanying the neuronal degeneration is an intracytoplasmic inclusion body, known as the Lewy body. A mutation was identified in the -synuclein gene, which codes for a presynaptic protein thought to be involved in neuronal plasticity, this mutation may cause a conformational change that renders alpha-synuclein more prone to self aggregation and deposition in Lewy bodies, which finally leads to oxidative stress and misfolding of B-synuclein. Parkin gene, mutations in this gene are reported in early autosomal-recessive form of PD, however these mutations do not degenerate Lewy bodies. The Parkin gene product (Parkin) is involved in protein degradation as a ubiquitin protein |
|---|
| Size | 100ug |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | Synuclein, alpha, Wild type, Recombinant, Human, 140aa (SNCA, 127750, P37840, MGC110988, NACP, PARK1, PARK4, non-A beta Component of AD Amyloid, NACP, Parkinson Disease Familial 1, PD1) |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | 209224 |
|---|
| Price | |
|---|
| Order / More Info | Synuclein, alpha, Wild type, Recombinant, Human, 140aa from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|